Neutrogena Oil-Free Acne Wash Cream Cleanser: what the package record adds

The official manufacturer statement is brief. It names the cream cleanser, gives a 6.7 oz size and describes a 2% salicylic-acid acne product. Its pore-cleaning and no-overdry statements are manufacturer representations. The short record is enough to identify the intended item, but it does not provide a complete ingredient declaration or a study report. Manufacturer statement. A brief official statement can be useful when its limited task is respected. It can establish the exact name and advertised active strength while leaving important formula and evidence fields for the label to answer. Its length does not justify substituting a more detailed page for a different product.

That limited scope matters more than adding extra detail from a similarly named product. The version-and-label guide explains why a shared brand family cannot establish an exact formula.

The August 2025 Kenvue record identifies Oil-Free Acne Wash Cream Cleanser with NDC 69968-0940. Its panel describes 189 g, also shown as 6.7 oz. Those fields connect the short manufacturer statement to a named cream-cleanser label. They do not describe another oil-free wash or a separate stress-control product. Named package and label.

The record is documentary evidence of what was posted. It is not an observation of current inventory or proof of the label on a reader’s container. For another format-identification question, see the La Roche-Posay cleanser review.

Salicylic acid 2% occupies the active field. The complete inactive list separately includes glycolic acid, panthenol, fragrance and menthol, among other entries. Their presence is useful formula information, but the list does not give an amount for each of them or demonstrate a finished-product result. Active and inactive fields. Listing glycolic acid in the base does not give an additional quantified active percentage. Similarly, naming panthenol does not establish that its presence cancels the label’s drying warning. The complete list supports ingredient identification without proving a balance of benefits and risks for an individual.

A familiar headline number is therefore only part of the product description. The two-percent comparison discusses the fields that remain open when products share an active strength. It does not turn the number of listed ingredients into a clinical ranking.

The principal panel advertises results in just one day. The examined panel does not state a participant count, define that result or supply a complete comparator and method. It would be premature to translate the headline into a measured pore outcome or a promised response for a reader. Principal-panel wording. The short manufacturer statement does not fill those study fields either. Deep-cleaning language and the one-day carton headline remain two kinds of advertising, rather than a single explained measurement of pore appearance. That is the precise evidence question left open by this record.

The absence here concerns the material actually examined, not a claim that no supporting work exists anywhere. The useful distinction is between a visible package statement and an available study account. The Clinique review offers a separate example of following an advertised endpoint back to its own footnote.

The short manufacturer statement says the product deep-cleans without overdrying. The label also carries drying cautions and an AHA warning field. The review preserves those as separate statements rather than treating the comfortable-sounding claim as permission to omit the warnings. Manufacturer comfort wording. Label context.

A caution field is relevant to understanding the record. It is not converted here into application directions, a prevention amount or a personal compatibility judgment. The source’s instructions remain outside this product-document review, and no firsthand tolerability experience is claimed.

The package data identify the 189 g presentation and a reported marketing start of September 1, 2025. FDA explains that a marketing start date concerns when a drug is reported to enter US commercial distribution. That is a different fact from manufacture, a reader’s purchase date or the present availability of stock. Package data. FDA directory explanation.

Keeping the field’s meaning intact avoids inventing a rollout history from one date. The supply-term guide likewise separates a quantity or commercial statement from what a particular transaction actually supplies.

FDA’s Drug Facts explanation separates statement of identity, net quantity, active amount and inactive ingredients. The Neutrogena label adds those kinds of detail to the manufacturer’s short account. It supports a specific cream-cleanser description while leaving the one-day outcome’s method and denominator unresolved in the examined material. Complete label. FDA field definitions.

This is useful information without a performance verdict. The complete base, precise name and package quantity can be reported now; a batch assay, fulfillment finding or complete clinical explanation cannot. Those limits stay attached to the item rather than being filled with an adjacent product’s evidence.